QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NASDAQ:CSTL

Castle Biosciences Stock Forecast, Price & News

$75.79
-3.38 (-4.27 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$74.74
Now: $75.79
$81.18
50-Day Range
$54.19
MA: $70.12
$81.48
52-Week Range
$21.01
Now: $75.79
$84.00
Volume265,487 shs
Average Volume240,213 shs
Market Capitalization$1.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.46
Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.

MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

420th out of 1,922 stocks

Medical Laboratories Industry

5th out of 39 stocks

Analyst Opinion: 1.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CSTL
CUSIPN/A
CIKN/A
Phone866-788-9007
Employees133
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.87 million
Cash Flow$0.14 per share
Book Value$4.98 per share

Profitability

Net Income$5.28 million

Miscellaneous

Market Cap$1.53 billion
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
$75.79
-3.38 (-4.27 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CSTL News and Ratings via Email

Sign-up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Castle Biosciences (NASDAQ:CSTL) Frequently Asked Questions

How has Castle Biosciences' stock been impacted by Coronavirus?

Castle Biosciences' stock was trading at $28.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CSTL shares have increased by 161.6% and is now trading at $75.79.
View which stocks have been most impacted by COVID-19
.

Is Castle Biosciences a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Castle Biosciences stock.
View analyst ratings for Castle Biosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Castle Biosciences?

Wall Street analysts have given Castle Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Castle Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Castle Biosciences' next earnings date?

Castle Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Castle Biosciences
.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) posted its quarterly earnings data on Saturday, November, 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.12. The company had revenue of $15.22 million for the quarter, compared to analysts' expectations of $15.31 million. Castle Biosciences had a negative trailing twelve-month return on equity of 2.69% and a negative net margin of 5.30%.
View Castle Biosciences' earnings history
.

What price target have analysts set for CSTL?

5 brokerages have issued 1-year price targets for Castle Biosciences' shares. Their forecasts range from $35.00 to $80.00. On average, they anticipate Castle Biosciences' share price to reach $69.00 in the next twelve months. This suggests that the stock has a possible downside of 9.0%.
View analysts' price targets for Castle Biosciences
or view Wall Street analyst' top-rated stocks.

Who are some of Castle Biosciences' key competitors?

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Square (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

Who are Castle Biosciences' key executives?

Castle Biosciences' management team includes the following people:
  • Mr. Derek J. Maetzold, Founder, CEO, Pres & Director (Age 58, Pay $1.14M)
  • Mr. Frank Stokes, Chief Financial Officer (Age 50, Pay $529.34k)
  • Ms. Kristen Oelschlager R.N., RN, Chief Operations Officer (Age 52)
  • Ms. Alice Bahner Izzo, VP of Marketing
  • Mr. Toby W. Juvenal, Chief Commercial Officer (Age 60)
  • Dr. Robert W. Cook, Sr. VP of R&D (Age 48)
  • Mr. Bernhard E. Spiess, Chief Bus. Officer (Age 60)

When did Castle Biosciences IPO?

(CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Castle Biosciences' stock symbol?

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

Who are Castle Biosciences' major shareholders?

Castle Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Creative Financial Designs Inc. ADV (0.01%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Castle Biosciences stock include Bernhard E Spiess, Bonnie H Anderson, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Frank Stokes, Joseph C Cook III, Mara G Aspinall, Mgc Venture Partners 2013 Gp, and Sofinnova Healthquest Partners.
View institutional ownership trends for Castle Biosciences
.

Which major investors are buying Castle Biosciences stock?

CSTL stock was purchased by a variety of institutional investors in the last quarter, including Creative Financial Designs Inc. ADV, and Nisa Investment Advisors LLC. Company insiders that have bought Castle Biosciences stock in the last two years include David S Kabakoff, and Mgc Venture Partners 2013 Gp,.
View insider buying and selling activity for Castle Biosciences
or or view top insider-buying stocks.

How do I buy shares of Castle Biosciences?

Shares of CSTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Castle Biosciences' stock price today?

One share of CSTL stock can currently be purchased for approximately $75.79.

How big of a company is Castle Biosciences?

Castle Biosciences has a market capitalization of $1.53 billion and generates $51.87 million in revenue each year. The company earns $5.28 million in net income (profit) each year or ($0.81) on an earnings per share basis. Castle Biosciences employs 133 workers across the globe.

What is Castle Biosciences' official website?

The official website for Castle Biosciences is castlebiosciences.com.

How can I contact Castle Biosciences?

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The company can be reached via phone at 866-788-9007 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.